anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To evaluate the diagnostic accuracy of the Node-RADS score and the utility of apparent diffusion coefficient (ADC) values in predicting metastatic lymph nodes (LNs) involvement in cervical cancer (CC) patients using magnetic resonance imaging (MRI). The applicability of the Node RADS score across three readers with different years of experience in pelvic imaging was also assessed.
MATERIAL AND METHODS: Among 140 patients, 68 underwent staging MRI, neoadjuvant chemotherapy and radical surgery, forming the study cohort. Node-RADS scores of the main pelvic stations were retrospectively determined to assess LN metastatic likelihood and compared with the histological findings. Mean ADC, relative ADC (rADC), and correct ADC (cADC) values of LNs classified as Node-RADS ≥ 3 were measured and compared with histological reports, considered as gold standard.
RESULTS: Sensitivity, specificity, positive and negative predictive values (PPVs and NPVs), and accuracy were calculated for different Node-RADS thresholds. Node RADS ≥ 3 showed a sensitivity of 92.8% and specificity of 72.5%. Node RADS ≥ 4 yielded a sensitivity of 71.4% and specificity of 100%, while Node RADS 5 yielded 42.9% and 100%, respectively. The diagnostic performance of mean ADC, cADC and rADC values from 78 LNs with Node-RADS score ≥ 3 was assessed, with ADC demonstrating the highest area under the curve (AUC 0.820), compared to cADC and rADC values.
CONCLUSION: The Node-RADS score provides a standardized LNs assessment, enhancing diagnostic accuracy in CC patients. Its ease of use and high inter-observer concordance support its clinical utility. ADC measurement of LNs shows promise as an additional tool for optimizing patient diagnostic evaluation.
The invention discloses a traditional Chinese medicine oral preparation for treating hemorrhinia and a preparation method thereof, and belongs to the field of traditional Chinesemedicinetreatment. The invention firstly discloses a recipe of thetraditional Chinese medicine oral preparation for treating the hemorrhinia. The recipe comprises root of Chinese thorowax and Chinese arborvitae twig and leaf. The invention provides a production technique of the preparation method of the traditional Chinese medicine oral preparation for treating the hemorrhinia. The production technique comprises the following steps of crushingChinese herbal medicines, soaking, extracting volatile oil, concentrating an extracting liquid into extractum, and directly or indirectly adding a pharmaceutically acceptableexcipient through a conventional technology, so as to prepare the clinically acceptable oral preparation. The preparation method has the advantages that the preparation method is simple, and the medicine for treating thehemorrhinia can be prepared.
Study subjects who have been infused with AGT103-T in a prior trial (AGT-HC-168) will be invited to stop their antiretroviral therapy in two phases. The first antiretroviral interruption will be closely monitored and if at any point study termination criteria are met, the study participant will be placed back on antiretroviral therapy. The second antiretroviral therapy will be instituted once the inclusion criteria are met. The aim of two antiretroviral interruptions is to allow for adequate sensitization of the cells and expansion of the pool of infused gene-modified cells. The two-phased ATI allows for a more robust suppression of HIV in study participants. Participants are monitored closely to determine if the autologous T cells with which they were previously infused, modify the kinetics of HIV rebound. The study participant will be closely monitored for the recurrence of HIV viremia and a decrease in their CD4 lymphocyte number.
BACKGROUND: Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in the individual susceptibility to the carcinogenic effects of tobacco. We characterized the germline profile of subjects presenting these extreme phenotypes with Whole Exome Sequencing (WES) and Machine Learning (ML).
METHODS: We sequenced germline DNA from heavy smokers who either developed lung adenocarcinoma at an early age (extreme cases) or who did not develop lung cancer at an advanced age (extreme controls), selected from databases including over 6600 subjects. We selected individual coding genetic variants and variant-rich genes showing a significantly different distribution between extreme cases and controls. We validated the results from our discovery cohort, in which we analysed by WES extreme cases and controls presenting similar phenotypes. We developed ML models using both cohorts.
FINDINGS: Mean age for extreme cases and controls was 50.7 and 79.1 years respectively, and mean tobacco consumption was 34.6 and 62.3 pack-years. We validated 16 individual variants and 33 variant-rich genes. The gene harbouring the most validated variants was HLA-A in extreme controls (4 variants in the discovery cohort, p = 3.46E-07; and 4 in the validation cohort, p = 1.67E-06). We trained ML models using as input the 16 individual variants in the discovery cohort and tested them on the validation cohort, obtaining an accuracy of 76.5% and an AUC-ROC of 83.6%. Functions of validated genes included candidate oncogenes, tumour-suppressors, DNA repair, HLA-mediated antigen presentation and regulation of proliferation, apoptosis, inflammation and immune response.
INTERPRETATION: Individuals presenting extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma show different germline profiles. Our strategy may allow the identification of high-risk subjects and the development of new therapeutic approaches.
FUNDING: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.
Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
This control-matched approach to the CogSMART group, currently utilized in Dr. Twamley's studies, has been well received by participants, with no significant increase in dropout rates. Additionally, control participants will receive the BrainHQ component, involving Internet Navigation Training previously employed by Dr. Vance consisting of 20 sessions lasting 30 minutes each aimed to provide no therapeutic benefit.
Environmental pollution poses risks to ecosystems. Among these risks, one finds neurotoxicity and damage to the lateral line structures of fish, such as the neuromast and its hair cells. Zebrafish (Danio rerio) is recommended as model species to be used in ecotoxicological studies and environmental biomonitoring programs aimed at assessing several biomarkers, such as ototoxicity. However, little is known about the history of and knowledge gaps on zebrafish ototoxicity. Thus, the aim of the current study is to review data available in the scientific literature about using zebrafish as animal model to assess neuromast toxicity. It must be done by analyzing the history and publication category, world production, experimental design, developmental stages, chemical classes, neuromasts and hair cell visualization methods, and zebrafish strains. Based on the results, number, survival and fluorescence intensity of neuromasts, and their hair cells, were the parameters oftentimes used to assess ototoxicity in zebrafish. The wild AB strain was the most used one, and it was followed by Tübingen and transgenic strains with GFP markers. DASPEI was the fluorescent dye most often applied as method to visualize neuromasts, and it was followed by Yo-Pro-1 and GFP transgenic lines. Antibiotics, antitumorals, metals, nanoparticles and plant extracts were the most frequent classes of chemicals used in the analyzed studies. Overall, pollutants can harm zebrafish's mechanosensory system, as well as affect their behavior and survival. Results have shown that zebrafish is a suitable model system to assess ototoxicity induced by environmental pollution.
The incidence of oropharyngeal cancer (OPSCC) has escalated in the past few decades; this has largely been triggered by high-risk human papillomavirus (HPV). Early cancer screening is needed for timely clinical intervention and may reduce mortality and morbidity, but the lack of knowledge about premalignant lesions for OPSCC poses a significant challenge to early detection. Biomarkers that identify individuals at high risk for OPSCC may act as surrogate markers for precancer but these are limited as only a few studies decipher the multistep progression from HPV infection to OPSCC development. Here, we summarize the current literature describing the multistep progression from oral HPV infection, persistence, and tumor development in the oropharynx. We also examine key challenges that hinder the identification of premalignant lesions in the oropharynx and discuss potential biomarkers for oropharyngeal precancer. Finally, we evaluate novel strategies to improve investigations of the biological process that drives oral HPV persistence and OPSCC, highlighting new developments in the establishment of a genetic progression model for HPV + OPSCC and in vivo models that mimic HPV + OPSCC pathogenesis.
Liver fibrosis remains a global health challenge due to its rapidly rising prevalence and limited treatment options. The orphan nuclear receptor Nur77 has been implicated in regulation of autophagy and liver fibrosis. Targeting Nur77-mediated autophagic flux may thus be a new promising strategy against hepatic fibrosis. In this study, we synthesized four types of Nur77-based thiourea derivatives to determine their anti-hepatic fibrosis activity. Among the synthesized thiourea derivatives, 9e was the most potent inhibitor of hepatic stellate cells (HSCs) proliferation and activation. This compound could directly bind to Nur77 and inhibit TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. In vivo, 9e significantly reduced CCl4-mediated hepatic inflammation response and extracellular matrix (ECM) production, revealing that 9e is capable of blocking the progression of hepatic fibrosis. Mechanistically, 9e induced Nur77 expression and enhanced autophagic flux by inhibiting the mTORC1 signaling pathway in vitro and in vivo. Thus, the Nur77-targeted lead 9e may serve as a promising candidate for treatment of chronic liver fibrosis.
Placebo is commercially available 0.9% Sodium Chloride Solution for Injection (USP). Placebo will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion. Placebo will be infused every 3 weeks for up to 7 cycles or 5 months, whichever is earlier.
The active ingredient in lansoprazole delayed-release orally disintegrating tablets is lansoprazole, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its molecular formula is C16H14F3N3O2S with a molecular weight of 369.37. Lansoprazole has the following structure:

Lansoprazole, USP is a white to brownish-white powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water. 

Lansoprazole is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. 

Lansoprazole is supplied in delayed-release orally disintegrating tablets for oral administration.

Lansoprazole delayed-release orally disintegrating tablets are available in two dosage strengths: 15 and 30 mg of lansoprazole per tablet. Each delayed-release orally disintegrating tablet contains enteric-coated pellets consisting of 15 or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: artificial strawberry flavor, aspartame1, citric acid monohydrate, crospovidone, hydroxypropyl cellulose, magnesium carbonate, magnesium stearate, mannitol, methacrylic acid copolymer type C, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium bicarbonate, sodium hydroxide, sodium lauryl sulfate, sodium starch glycolate (potato), sugar spheres (corn starch and sucrose), talc, triethyl citrate and yellow iron oxide.

1Phenylketonurics:Lansoprazole delayed-release orally disintegrating tablets contain phenylalanine 3.37 mg per 15 mg tablet and 6.74 mg per 30 mg tablet.
The invention concerns (.alpha.-aminophosphino) peptide derivative compounds of general formula (I) wherein: R¿1? and R¿2? represent each a hydrogen atom or together form an imine with the adjacent nitrogen atom; R¿3? represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all said groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally a methyl group substituted by an aromatic or saturated heterocyclic group; R¿4? represents a CH(X)-O-C(O)-Y group or a CH¿2?CH¿2?-S-C(O)-W group; R¿5? represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all said groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally a methyl group substituted by an aromatic or unsaturated heterocyclic group; R¿6? and R¿7? can in particular represent a hydrogen atom, an alkyl group, a phenyl group substituted or not; R¿8? represents an alkyl, alkenyl, phenyl or benzyl group; n = 0 or 1, in the form of enantiomers, diastereoisomers or racemic mixtures, their salts, the method for preparing them and their therapeutic applications.
Individuals in this group will be taught breathing exercises (diaphragmatic breathing, thoracic expansion, pursed-lip breathing, and respiratory control) after the assessments, and they will be informed about performing breathing exercises for 15 minutes a day, every day of the week. Patients will be asked to keep a "treatment diary" to control regular breathing exercises. Individuals will be re-evaluated after 2 months.
Composition comprises at least one double stranded RNA oligonucleotide (I) associated with a cationic particle of =1 mu m in size and 10-80 mV of zeta potential. Composition comprises at least one double stranded RNA oligonucleotide (I) (SEQ ID No. 1-48 comprising one of 48 fully defined 19-25 amino acid sequences given in the specification) associated with a cationic particle of =1 mu m in size and 10-80 mV of zeta potential. An independent claim is included for cosmetic process to bleach, clear up the color and/or uniform the color of a browned skin comprising topical application of (I). ACTIVITY : Dermatological. MECHANISM OF ACTION : Tyrosinase expression inhibitor. The ability of (I) on the degradation of tyrosinase messenger RNA was tested. The results showed that the double stranded RNA oligonucleotide of SEQ ID No. 43 comprising a fully defined 25 amino acid sequences given in the specification, exhibited 99.1% inhibition of tyrosinase.
After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers. The symptoms monitored in the project were nausea/vomiting, pain, sore mouth, diarrhea, constipation, depressed mood, anxiety, trouble sleeping, and fatigue. The study randomly assigned participants into either the intervention group or the group that received usual care from their oncology providers without alert notifications. All participants called the automated system daily to report their symptom presence, severity, and distress. When participants in the intervention group rated symptoms at moderate (4-7) to severe (8-10) levels an e-mail alert report of their symptom information was sent to the participant's medical oncologist and oncology nurse. The usual care group also reported symptoms daily to the automated system but their information was not sent to the providers. Participants in the usual care group were told daily to call their oncology provider if they had concerns about their symptoms. The two study groups were compared over chemotherapy cycles 2 and 3 on symptom presence, severity, and distress. Functional status, patient reported degree of symptom interference with normal activities, and work attendance if they had indicated that they worked during their treatment were also recorded. In addition, the groups were compared for the number and purpose of unscheduled patient-provider contacts, visits to the emergency department or urgent care facility, and unscheduled hospitalizations.
Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
The Refining an Asynchronous Narrative-Based Intervention for Adjusting to Heart Failure Chronic Illness to Advance Behavioral Health Equity study is a NIH Intervention Stage 1B intervention study design with randomization into two arms: a sham control (SC) and an intervention arm (IA). The study investigators will be recruiting up to 64 participants adjusting to living with heart failure. All participants will be randomized to the SC or IA arms (1:1 randomization). All participants will be asked to complete measurements at baseline (T0), three months (T3), and six months (T6). Measurements at T0 include demographic information, Personal Health Questionnaire-9 item (PHQ9), General Anxiety Disorder-7 item (GAD7), Kansas City Cardiomyopathy Questionnaire (KCCQ), and the Self Care Heart Failure Index (SCHFI). T3 measurements include: PHQ9, GAD7, KCCQ, and SCHFI. Measurements at T6 include: PHQ9, GAD7, SCHFI, KCCQ, and self-reported access to care and healthcare utilization. Measurements will be administered by email link using REDCap (an online database administered by the University of Colorado).

Intervention and sham control groups will receive biweekly text response prompts. The IA will have tailored responses crafted by the social work psychotherapists. The SC group will not have feedback or tailored responses.

Study participants who complete Week 8 will also be asked to participate in a semi-structured interview at T3. The study investigators will integrate both quantitative and qualitative results as a convergent mixed methods analysis study. In the mixed analyses, The study investigators will pay attention to points of integration in the qualitative subsample of the population, patterns of behavioral outcome scores, context, geolocation characteristics, access to care experience; and frequency of self-schema, world-schema, and self-care of illness compared across aims.
A polypeptide, enzymal in nature and useful in the treatment of arthritis (Group VI), has a molecular weight of 10,000 to 11,000 and approximately two glutamic acid residues per aspartic acid residue and also contains a minor proportion of arginine, lysine and glycine residues, it contains 60,5% glutamic acid, 30,5% aspartic acid, 3,3% arginine, 3,3% lysine and 2,4% glycine and is obtained from beef liver.  The beef liver has the connective tissue removed manually and is then treated for the removal of proteins, albuminoids, histones, basic amino acids, proteoses and peptones, a water-miscible alcohol or ketone is added to the liquid residue in up to 60% concentration, the material allowed to stand at a low temperature for some hours until it forms a top liquid layer of an orange-red colour separated by a solid water of a grey or olive green colour from a lower liquid layer of a greenish-yellow colour, separating the upper liquid layer, adding thereto a water-miscible solvent which is an alcohol or ketone and cooling to a low temperature for some hours to form a flucculent, slightly pinkish precipitate, separating the solid from the liquid, macerating the solid with an aqueous liquid having a pH of 7 to 9, separating the liquid obtained and subjecting it to dialysis, and thereafter heating the dialysed liquid to 43 to 49 DEG C. until a heavy flocculent precipitate forms, separating the liquid, subjecting it to distillation at a reduced pressure and a temperature not exceeding 43 DEG C. until a solid residue is formed.ALSO:A polypeptide useful in the treatment of arthritis and having a molecular weight of 10,000 to 11,000 and approximately two glutamic acid residues per aspartic acid residue and also containing a minor proportion of arginine, lysine and glycine residues, contains 60.5% glutamic acid, 30.5% aspartic acid, 3.3% arginine, 3.3% lysine and 2.4% glycine and is isolated from beef liver.  The beef liver has its connective tissue removed manually and is then treated for the removal of proteins, albuminoids, histones, basic amino acids, proteoses and peptones, a water-miscible alcohol or ketone is iadded to the liquid residue in a concentration not exceeding 60% by volume, the material is allowed to stand at a low temperature, e.g. 3 DEG  C. for some hours, e.g. 12 hours until it forms a top liquid layer of an orange-red colour separated by a solid wafer of a grey or olive-green colour from a lower liquid layer of a greenish-yellow colour, separating the upper liquid layer, adding thereto a water-miscible alcohol or ketone, cooling to a low temperature, e.g. 3 DEG  C. to form a flocculent slightly pinkish precipitate, separating the solid from the liquid, macerating the solid with an aqueous liquid having a pH of 7 to 9, separating the liquid obtained and subjecting it to dialysis, and thereafter heating the dialysed liquid to 43 DEG  to 49 DEG  C. until a heavy flocculent precipitate forms, separating the liquid, subjecting it to distillation at a reduced pressure and temperature not exceeding 43 DEG  C. until a solid residue is formed.
PROBLEM TO BE SOLVED: To provide an improved pasteurization process for pasteurizing microbial cells which improves the quality of oil and hardly requires energy.SOLUTION: A pasteurization process has a first heating stage, a second plateau stage at which cells are held at a (maximum and) constant temperature, and a third cooling stage. Both the heating and cooling stages are rapid, with the temperature of the cells being 40 to 80°C in 30 minutes or less in the heating stage. The heating stage has at least 0.5°C/min and the cooling stage has at least -0.5°C/min. The plateau maximum temperature is 70 to 85°C. Plotting the pasteurization protocol on a time (t, minutes) versus temperature (T, °C) graph provides a trapezoid having an area less than 13000°C min. This results not only in a smaller energy input (and a reduction in costs), but in a better quality (and less oxidized) oil having a peroxide value (POV) of less than 1.5 and an anisidine value (AnV) of less than 1.0.SELECTED DRAWING: None